“Catheter Related Blood Stream Infections Epidemiology” report has been added to DelveInsight
Catheter-related bloodstream infection (CRBSI) is defined as the presence of bacteremia originating from an intravascular (I.V.) catheters. CRBSI refers to bloodstream infection attributed to an intravascular catheter by quantitative culture of the catheter tip or by differences in growth between catheter and peripheral venipuncture blood culture specimens. Also known as catheter-related sepsis, it is the most common cause of nosocomial bacteremia.
Catheter Related Blood Stream Infections Epidemiology: Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Risk factors associated with the development of catheter-associated infections can be divided into host-related problems and device-related issues. The host-related risk factors include immune deficiency (due to chemotherapy-induced neutropenia, bone marrow transplantation, etc.), chronic illnesses (diabetes, end-stage renal disease, and short-gut syndrome), and loss of skin integrity, very-low-birth-weight (VLBW) infants, and others.
CRBSI arises from bacterial seeding from biofilms that form on either the inside or outside of indwelling catheters. Biofilms allow the sessile bacteria to survive in a hostile environment and grow in a languidly. The susceptibility of bacteria in a biofilm to antimicrobial agents is dramatically decreased, by at least 10–100-fold. Adherence of contaminating bacteria to the CVC is a prerequisite for biofilm formation to take place. In the first 2 weeks after catheter placement, the formation of a biofilm on the outside of the CVC and subsequent surface migration of bacteria into the bloodstream is vital for CRBSI to occur.
For CRBSI various measures have been implemented to reduce the risk of occurrence which includes the use of utmost barrier, precautions during catheter insertion, effective cutaneous anti-sepsis, and preventive strategies based on inhibiting micro-organisms originating from the skin or catheter hub from adhering to the catheter.
- As per the DelveInsight’s estimates, the incident population of CRBSI in the 7MM was found to be 674,347, in 2020.
- The estimates show a higher incidence of CRBSI in the US with 330,686 cases, in 2020.
- As per the analysis, in the US, the incidence of Gram-positive bacteria is more than Gram-negative bacteria and very few are affected with candida species (fungi). Methicillin susceptible Staphylococcus aureus occupies the maximum patient pool among the Gram-positive bacteria, with 143,072 cases of this category, in 2020.
- Total Incident Population of CRBSI in the 7MM [2018–2030]
- Diagnosed Incidence of CRBSI by Causative Pathogens in the 7MM [2018–2030]
- Total Diagnosed Incident Population of CRBSI in the 7MM [2018–2030]
Table of content
- Key Insights
- Executive Summary of Catheter-Related Bloodstream Infections (CRBSIs)
- Catheter-Related Bloodstream Infections (CRBSIs): Disease Background and Overview
- Patient Journey
- Epidemiology and Patient Population
- Treatment Algorithm, Current Treatment, and Medical Practices
- KOL Views
- Unmet Needs
- DelveInsight Capabilities
- About DelveInsight
The objective of updating DelveInsight coverage is to ensure that it represents the most up-to-date vision of the industry possible. The DelveInsight is a fully integrated solution for comprehensive intelligence on various pharmaceutical products, both in the market and in the pipeline, across the globe.
View Latest Reports
- Otitis Media Market
- Myotonic Dystrophy Market
- Medical Marijuana Market
- Hemodialysis Catheters Pipeline
- Hand foot syndrome/palmar-plantar erythrodysesthesia syndrome Market
- Biotech Consulting
DelveInsight is a Business Consultant company and serves as a Knowledge partner across the value chain of the Pharmaceutical Industry. With the use of proprietary databases and analytical models, DelveInsight provides cutting-edge market and pipeline analysis and API intelligence across all therapy areas to the Pharma and biotech sector, helping clients to quantify market events and evaluate their impact on the valuation of products, portfolios, and companies.